| Diabetes Mellitus, Non-Insulin-Dependent

Humalog 75/25 vs Soliqua

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.
Deep comparison between: Humalog vs Soliqua 100/33 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsSoliqua 100/33 has a higher rate of injection site reactions vs Humalog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliqua 100/33 but not Humalog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Humalog
Soliqua 100/33
At A Glance
SC injection
Twice daily
Insulin analog
SC injection
Once daily
Basal insulin + GLP-1 receptor agonist
Indications
  • Diabetes Mellitus, Non-Insulin-Dependent
  • Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Inject SC within 15 minutes before a meal into abdominal wall, thigh, upper arm, or buttocks; typically dosed twice daily; individualize dose based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus, Non-Insulin-Dependent 15 units SC once daily for patients naive to basal insulin or GLP-1 receptor agonist, on a GLP-1 receptor agonist, or on <30 units basal insulin daily; 30 units SC once daily for patients on 30-60 units basal insulin daily; titrate by 2-4 units weekly; max 60 units (60 units insulin glargine/20 mcg lixisenatide) daily; inject within 1 hour prior to first meal of the day.
Contraindications
  • During episodes of hypoglycemia
  • Previous hypersensitivity reactions to HUMALOG Mix75/25 or any of its excipients
  • Hypoglycemia episodes
  • Serious hypersensitivity to insulin glargine, lixisenatide, or any excipient in SOLIQUA 100/33
Adverse Reactions
Most common Hypoglycemia
Serious Severe anaphylaxis, hypokalemia
Postmarketing Lipodystrophy, localized cutaneous amyloidosis, injection site reactions, peripheral edema, weight gain, anti-insulin antibody formation
Most common (>=5%) Nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache, hypoglycemia
Serious Anaphylaxis, serious hypersensitivity, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, hypokalemia, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Localized cutaneous amyloidosis (insulin glargine); acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, dysgeusia, dysesthesia, pulmonary aspiration, acute renal failure, alopecia (lixisenatide)
Pharmacology
Insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake by skeletal muscle and fat and inhibiting hepatic glucose production, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
SOLIQUA 100/33 combines insulin glargine, a basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, with lixisenatide, a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Humalog
  • Covered on 5 commercial plans
  • PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
View full coverage details ›
Soliqua 100/33
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (7/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Humalog
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
View full coverage details ›
Soliqua 100/33
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
View full coverage details ›
Humana
Humalog
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (2/3) · Qty limit (0/3)
View full coverage details ›
Soliqua 100/33
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Humalog.
No savings programs available for Soliqua 100/33.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
HumalogView full Humalog profile
Soliqua 100/33View full Soliqua 100/33 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.